UroGen Pharma

Company Overview

Snapshot

Founded in April 2004 by Asher Holtzer, UroGen Pharma operates with 201–500 employees. The company has raised a total of $522.2 million across 11 funding rounds from 8 investors. In March 2026, UroGen Pharma refinanced its debt with a $250 million facility.

Business overview

UroGen Pharma is a biotech company focused on developing novel solutions for specialty cancers and urologic diseases. The company's core technology is RTGel, a proprietary sustained-release, hydrogel-based platform designed to enhance the therapeutic profiles of existing drugs by enabling longer exposure of urinary tract tissue to medications. UroGen's lead product candidates, UGN-101 (MitoGel) and UGN-102 (VesiGel), aim to treat non-muscle-invasive urothelial cancer, including low-grade upper-tract urothelial carcinoma and bladder cancer, through non-surgical means. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, focusing on drug discovery, development, and delivery.

Strategic signal

In October 2024, the FDA accepted UroGen's New Drug Application for UGN-102, a significant regulatory milestone that validates the company's progress in developing a potential non-surgical treatment for bladder cancer. This acceptance signals to investors the advancement of UroGen's pipeline and its potential to address unmet needs in urologic oncology, positioning the company for future market entry and revenue growth.

Company Intelligence Q&A

What was a key financial event for UroGen Pharma in March 2026?

In March 2026, UroGen Pharma refinanced its debt with a $250 million facility at an 8.25% rate.

What was a significant regulatory milestone for UroGen Pharma in October 2024?

In October 2024, the FDA accepted UroGen Pharma's New Drug Application for UGN-102, a potential non-surgical treatment for bladder cancer.

What was the outcome of the ENVISION Trial for UGN-102, published in October 2024?

In October 2024, results from the ENVISION Trial for UGN-102 were published in the Journal of Urology, reporting an 82.3% duration of response 12 months after achieving complete response for UGN-102, indicating its potential as the first FDA-approved non-surgical treatment for LG-IR-NMIBC.

What was a key development for UroGen Pharma's UGN-103 in November 2025?

In November 2025, UroGen Pharma reported a 77.8% three-month complete response rate from the Phase 3 UTOPIA Trial of UGN-103 and received FDA agreement on the NDA submission strategy for recurrent LG-IR-NMIBC based on this trial.

When did UroGen Pharma begin trading publicly on NASDAQ?

UroGen Pharma became a public company and began trading on NASDAQ in May 2017.